The Wet Age-related Macular Degeneration market is expected to show positive growth owing to increased prevalence and the anticipated launch of novel therapies during the forecast period (2021-30)

December 08 15:04 2021
The Wet Age-related Macular Degeneration market is expected to show positive growth owing to increased prevalence and the anticipated launch of novel therapies during the forecast period (2021-30)
Wet Age-related Macular Degeneration Market
The Wet AMD market size is anticipated to increase owing to the launch of emerging therapies.

DelveInsight’s Wet Age-related Macular Degeneration market report provides an in-depth understanding of Wet Age-related Macular Degeneration, historical and forecasted epidemiology, and market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also discusses current Wet-AMD symptom treatment practices and algorithms, market drivers, market barriers, and unmet medical needs.

Some of the Key Highlights from the Wet Age-related Macular Degeneration Market Report

  • As per DelveInsight’s Wet Age-related Macular Degeneration epidemiology insights, the total diagnosed prevalent population was estimated to be 4,426,968 in the 7MM in 2020.

  • Among the EU5 countries, Germany had the highest Wet AMD prevalent population while Spain had the least in 2020.

  •  As per the estimates, the highest number of WET AMD cases were reported in the age group of 61-70 years in the US in 2020.

  • Some of the leading players in the global Wet AMD market in the late phase of clinical development include Roche, Kodiak Sciences, REGENXBIO, Chengdu Kanghong Biotech, Opthea, among others.

  • Key Wet AMD pipeline therapies that are soon to be available in the market include Faricimab, Conbercept, KSI-301, OPT-302, RGX-314, and others.

  • KSI-301 is a novel anti-VEGF biologic that is designed to inhibit VEGF quickly while also providing an extended duration of action to reduce the burden of frequent anti-VEGF injections. It is being developed and investigated in phase III studies by Kodiak Sciences. 

  • Faricimab (RG7716), developed by Roche, is the first bispecific antibody developed using CrossMab technology, is specifically designed for intravitreal use to bind to and neutralize both angiopoietin-2 (Ang-2) and VEGF-A with high potency and specificity.

For more insights into the disease, request for the sample @ Difference between Wet and Dry AMD

The Wet AMD market report also covers current treatment practices, emerging drugs, and their market share of individual therapies, as well as current and forecasted Wet-AMD symptoms market size from 2017 to 2030, segmented by seven major markets.

Wet Age-related Macular Degeneration: Overview

Wet Age-related Macular Degeneration is a type of age-related macular degeneration characterized by sudden central vision loss caused by abnormal blood vessels that bleed or leak fluid, causing the macula to swell and damage. It is also known as neovascular AMD and accounts for approximately 10% of AMD cases but nearly 90% of AMD-related central vision loss. Although non-neovascular or atrophic AMD accounts for 80% of patients, neovascular AMD accounts for nearly 90% of the severe, central visual acuity loss associated with AMD.

Wet Age-related Macular Degeneration Epidemiology Segmentation

The Wet Age-related Macular Degeneration report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Wet Age-related Macular Degeneration Total Prevalent Cases 

  • Wet Age-related Macular Degeneration Gender-Specific Cases

  • Wet Age-related Macular Degeneration Age-Specific Cases

Wet Age-related Macular Degeneration Treatment Landscape

Wet AMD has no cure, but an appropriate treatment could delay disease progression, avoiding the negative impact of vision loss on these patients’ quality of life. The current Wet AMD treatment options include Angiogenesis inhibitors (Lucentis, Eylea, Macugen, and Boevu), Photodynamic therapy (PDT), Laser photocoagulation surgery, antioxidant vitamins, and other nutrients. Some off-label drugs such as Avastin are also used as a treatment for Wet AMD.

Wet Age-related Macular Degeneration Market

  • The Wet AMD market size was found to be USD 7,459  million in the 7MM in 2020.

  • Among the 7MM, the US accounted for 31.1% of the overall Wet AMD market size in 2020.

  • Among EU5 countries, Germany accounted for the highest Wet AMD market share while Spain captured the least Wet AMD market size in 2020.

  • The Wet AMD market size is anticipated to increase owing to the launch of emerging therapies such as Faricimab, Conbercept, and others during the study period (2018-2030).

Wet Age-related Macular Degeneration Pipeline Therapies and Key Companies 

  • Faricimab: Roche

  • Conbercept: Chengdu Kanghong Biotech

  • KSI-301: Kodiak Sciences

  • OPT-302: Opthea

  • RGX-314: Regenxbio

Learn more about the emerging drugs and companies @ Wet AMD Treatment Breakthroughs

Wet Age-related Macular Degeneration Market Drivers

  • Drugs in Pipeline

  • Personalized treatment

  • Increased WET AMD Prevalence

  • Genetic Therapy

Wet Age-related Macular Degeneration Market Barriers

  • Cost of Therapy

  • Launch of Biosimilars

  • Future competition among similar drugs

Scope of the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Wet AMD Key Companies: Roche, Kodiak Sciences, REGENXBIO, Chengdu Kanghong Biotech, Opthea, among others. 

Wet AMD Key Pipeline Therapies: Faricimab, Conbercept, KSI-301, OPT-302, RGX-314, and others.

Wet AMD Segmentation: By Geography, Wet AMD drugs

Analysis: Comparative and conjoint analysis of  Wet AMD emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents 

1.

Key Insights

2.

Executive summary

3.

Organizations

4.

Wet Age-related Macular Degeneration (wet AMD): Market Share Overview at a Glance

5.

Wet Age-related Macular Degeneration (wet AMD): Market Overview at a Glance

6.

Wet AMD Epidemiology and Patient Population

7.

Treatment of Wet Form Age-related Macular Degeneration (wet AMD)

8.

Wet AMD Unmet Needs

9.

Wet AMD Marketed drugs

10.

Wet AMD Emerging Therapies

11.

Other Wet AMD Promising Therapies

12.

Wet Age-related Macular Degeneration (wet AMD): Seven Major Market Analysis

13.

Wet AMD Seven Major Market Outlook

14.

Wet AMD Market Drivers

15.

Wet AMD Market Barriers

16.

SWOT Analysis

17.

Wet AMD Market Access

18.

Case Study

19.

KOL Views

20.

Bibliography

21.

Appendix

22.

DelveInsight Capabilities

23.

Disclaimer

24.

About DelveInsight

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Age-related Macular Degeneration (AMD) Market

DelveInsight’s “Age-related Macular Degeneration (AMD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Age-related Macular Degeneration (AMD), historical and forecasted epidemiology as well as the Age-related Macular Degeneration (AMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/